Automated Suturing Devices Market Size & Share 2026-2035

Automated Suturing Devices Market Size

The automated suturing devices market was valued at USD 628.4 million in 2025 and is projected to reach USD 1.2 billion by 2035, expanding at a CAGR of 6.7% during 2026–2035.

Growth is tied to the increasing need to complete tissue approximation reliably in minimally invasive, endoscopic, and robotic procedures, where access constraints and operating-room throughput make manual suturing more demanding.

Procedure demand provides the underlying volume base. More than 234 million surgical procedures are performed globally each year, while the volume of conditions requiring surgery was projected to increase by more than 45% by 2030. ^{[1]World Health Organization, EB135/3 Executive Board Document. apps.who.int} The addressable opportunity, however, is not simply a function of total procedures. Adoption depends on whether hospitals can justify the device's incremental cost through lower setup burden, dependable closure performance, or improved procedure flow in specialties with repeatable, high-volume workflows.

Robotic surgery is changing the purchasing context from a standalone instrument decision to a platform-compatibility decision. Hospitals that introduce robotic-assisted surgery have recorded a rise in minimally invasive surgery rates from 60.5% to 65.8%, compared with a marginal increase among hospitals without robotic adoption. This expands the procedural settings in which controlled, reproducible tissue closure can be commercially relevant, particularly in gastrointestinal, gynecological, urological, and hernia-related interventions.

Trauma also sustains demand for surgical capacity, although it does not automatically translate into automated-device penetration. Road traffic injuries cause approximately 1.16 million deaths annually and 20–50 million non-fatal injuries, with 92% of road fatalities occurring in low- and middle-income countries. ^{[2]World Health Organization, Road Traffic Injuries. who.int} The resulting need for surgical care is substantial, but the same regions often face the financing, infrastructure, and training constraints that limit uptake of higher-cost surgical technologies.

The forecast also reflects an uneven geographic opportunity. Trauma and unmet surgical need are concentrated in markets where advanced equipment access remains constrained, whereas the largest near-term revenue pools are in systems that can support capital equipment, clinical training, sterile supply, and recurring procedural expenditure. Suppliers therefore face two distinct commercial tasks: defend workflow integration in developed markets and develop economically viable access models for emerging systems.

Key Drivers

The growing surgical caseload supports demand for instruments that can make closure more repeatable without adding complexity to the procedure. An estimated additional 143 million surgical procedures are needed annually worldwide to address unmet need. In mature systems, the practical implication is greater pressure to standardize high-volume workflows; in underserved systems, it reinforces the need for scalable surgical capacity but does not by itself remove affordability barriers.

Robotic-assisted surgery increases the importance of instrument integration and surgeon control. Johnson & Johnson MedTech received FDA investigational device exemption approval in November 2024 for the OTTAVA robotic surgical system, which is designed to integrate Ethicon instrumentation with the Polyphonic digital ecosystem. ^{[3]Johnson & Johnson MedTech, Johnson & Johnson MedTech Receives IDE Approval for OTTAVA Robotic Surgical System. jnj.com} Separately, use of knotless tissue-control devices in robotic colorectal, hysterectomy, and hernia procedures tripled between 2015 and 2022; the associated study reported reductions in operating-room time of 19.1 minutes for hysterectomy and 17.3 minutes for hernia repair. These findings indicate that automation gains traction when it supports a measurable workflow objective rather than merely adding a new instrument category.

Trauma creates demand across emergency and reconstructive surgical pathways. The burden is especially material in lower-income geographies, where trauma accounts for more deaths than HIV, tuberculosis, and malaria combined, and low- and middle-income countries account for 90% of trauma deaths. For device suppliers, this creates a tension: the clinical need is broad, but conversion depends on the availability of trained teams, surgical facilities, and procurement budgets capable of supporting automated closure technologies.

Key Restraints

The cost barrier extends beyond the purchase price of an individual suturing device. A review of robotic surgery in low- and middle-income countries reported that new robotic platforms can cost more than USD 1 million and add USD 3,000–5,000 per procedure. ^{[4]Annals of Medicine and Surgery, Robotic Surgery in Low- and Middle-Income Countries. sciencedirect.com} Even where automated suturing is not tied to a robotic platform, capital constraints, consumable budgets, sterilization requirements, and surgeon training influence total cost of ownership. This favors products that can demonstrate a clear procedural or turnover benefit within existing budgets.

Limited developing-region adoption is principally a health-system constraint rather than a lack of clinical need. Research on barriers to robot-assisted minimally invasive surgery in Africa identifies limited healthcare budgets, high device costs, inadequate infrastructure, and insufficient training as persistent obstacles. The adoption gap can widen when suppliers offer advanced platforms without adaptable service, training, or financing arrangements. Lower-cost product architectures and phased deployment models may therefore be more relevant than a direct replication of developed-market commercialization models.

This creates a bifurcated growth path. Hospitals with established robotic programs can assess automated suturing in terms of integration, procedure time, and clinical workflow. Providers without that infrastructure must first solve more fundamental access and financing questions. The commercial advantage will therefore lie with suppliers that can align product design and contracting with the infrastructure maturity of each care setting.

Automated Suturing Devices Market Segment Analysis

By Product Type

Disposable devices accounted for 64.5% of revenue in 2025 and are projected to exceed USD 820.7 million by 2035, advancing at a 7.3% CAGR. Their position reflects the operational value of reducing reprocessing steps and simplifying turnover in high-throughput settings. The clinical and economic case is strongest where infection-control protocols, procedure frequency, and staff time make single-use workflow consistency more valuable than reuse economics.

Reusable devices generated USD 223.2 million in 2025. Their relevance remains greatest in institutions with dependable sterilization capacity and enough utilization to spread maintenance and reprocessing costs across procedures. The disposable-versus-reusable decision is consequently less a universal product preference than a facility-level trade-off between sterile-services infrastructure, utilization intensity, and recurring consumable expenditure.

By Application

Gastrointestinal surgery held the largest application share at 32.6% in 2025. The segment benefits from the importance of secure closure in laparoscopic and endoscopic procedures, as well as the move toward technologies that support controlled tissue management in confined anatomical spaces. Nitinotes' CE Mark approval for EndoZip in endoscopic sleeve gastroplasty illustrates the continued expansion of automated suturing concepts into procedure-specific endoscopic pathways. ^{[5]PR Newswire, Nitinotes Receives CE Mark Approval of EndoZip, the First Fully Automated Suturing System for Endoscopic Sleeve Gastroplasty. prnewswire.com}

Cardiovascular surgery is projected to expand at a 5.9% CAGR through 2035. Although its growth rate trails faster-growing application areas, cardiovascular procedures retain a demanding technical profile in which closure consistency and instrument control are important. Gynecological surgery accounted for 17.3% of 2025 revenue and benefits from the broader adoption of minimally invasive and robotic techniques, including hysterectomy workflows where knotless tissue-control devices have demonstrated operating-room time reductions.

Orthopedic, ophthalmic, and other surgical applications broaden the market's clinical base but require targeted value propositions. Orthopedic demand increasingly intersects with outpatient migration, while ophthalmic applications depend on precision, material choice, and specialty-specific surgeon preferences. Other surgical applications offer expansion potential where automated closure can solve a defined workflow or access problem rather than substitute for manual suturing indiscriminately.

By End Use

Hospitals held 62.9% of market revenue in 2025 and are expected to reach USD 743.6 million by 2035. Their scale, surgical breadth, and ability to invest in robotics, training, and integrated operating-room infrastructure support early technology adoption. Hospitals also remain central for complex gastrointestinal, cardiovascular, and trauma procedures that are less easily transferred to outpatient settings.

Ambulatory surgical centers are expected to grow at a 7.3% CAGR. The U.S. had 6,308 Medicare-certified ambulatory surgical centers in 2023, up 2.5% from 2022, while joint surgeries performed in these facilities rose 50% and orthopedic procedures increased 11%. ^{[6]Medicare Payment Advisory Commission, ASC Services Status Report. medpac.gov} As procedure migration continues, device design must accommodate fast setup, predictable use, and cost discipline. Specialty clinics and other end users represent more selective opportunities, typically where procedure concentration or physician specialization can support dedicated adoption.

Application performance will remain differentiated. Gastrointestinal and gynecological procedures are well positioned to benefit from minimally invasive and endoscopic technology adoption, whereas cardiovascular use reflects higher technical demands and a more deliberate adoption cycle. Suppliers that prioritize a limited number of procedure-specific workflows, rather than a broad undifferentiated portfolio, are more likely to establish credible clinical and economic differentiation.

Automated Suturing Devices Market Regional Analysis

North America

North America generated USD 210.09 million in 2025, representing 33.43% of global revenue, and is projected to reach USD 385.58 million by 2035. The U.S. accounted for USD 191.62 million in 2025, while Canada contributed USD 18.47 million. The region's lead reflects a dense base of advanced hospitals, outpatient infrastructure, and robotic-surgery investment. U.S. market momentum is reinforced by the expansion of ambulatory surgical centers and by ongoing investment in robotic platforms. Canada is expected to grow faster than the U.S. through 2035, albeit from a much smaller base.

Europe

Europe recorded USD 172.94 million in 2025 and is expected to reach USD 312.53 million by 2035. Germany, the UK, France, Spain, Italy, and the Netherlands form the core addressable markets. The UK's robotic adoption illustrates the region's direction: 67% of NHS trusts used robotic systems in 2024, compared with 20% in 2014, while robotic procedures rose from 3,622 to 36,209 over the same period. ^{[7]PubMed, National Adoption of Robotic-Assisted Surgery in the UK, 2014-2024. pubmed.ncbi.nlm.nih.gov} Europe's growth is therefore supported by a maturing installed base, though country-level procurement and reimbursement conditions will shape the pace of device conversion.

Asia Pacific

Asia Pacific is projected to grow at the fastest regional CAGR, 7.94%, increasing from USD 145.48 million in 2025 to USD 311.77 million in 2035. China, Japan, India, Australia, and South Korea combine large surgical needs with unequal access to advanced care. Regional surgical-planning initiatives recognize that surgical care is needed to address one-third of the global disease burden. Demand will be concentrated first in advanced urban centers and medical-tourism hubs, then broaden as infrastructure, clinician training, and payment capacity improve.

Latin America

Latin America is expected to expand from USD 64.88 million in 2025 to USD 127.37 million by 2035. Brazil, Mexico, and Argentina are the principal markets, but geographic access gaps remain material. Brazil's surgical system has documented regional disparities in service allocation, while Mexico's healthcare system comprises more than six subsystems and continues to expand surgical access through IMSS-Bienestar in rural areas. These conditions make market development dependent on localized distribution, public-sector procurement dynamics, and clinical-training support.

Middle East and Africa

Middle East and Africa is forecast to grow from USD 35.03 million in 2025 to USD 67.63 million by 2035. Saudi Arabia, the UAE, and South Africa provide the most immediate opportunities, although the region remains heterogeneous. Saudi Arabia allocated SR260 billion, approximately USD 69.3 billion, to health and social development in 2025, while Vision 2030 targets privatization of 290 hospitals. Investment-led modernization can support advanced surgical adoption in Gulf markets, whereas trauma burden and infrastructure constraints will continue to limit the speed of broad-based regional penetration.

Asia Pacific offers the clearest share-expansion opportunity, rising from 23.15% of global revenue in 2025 to 25.88% by 2035. Its trajectory is contingent on infrastructure and access, not merely population scale. Latin America and Middle East and Africa require more segmented strategies: private-sector modernization and referral centers can support adoption, while uneven public infrastructure restricts broad substitution of manual closure techniques.

Automated Suturing Devices Market Share & Competitive Landscape

The competitive landscape includes Anchora Medical, Boston Scientific, ErgoSuture, Johnson & Johnson MedTech, LSI Solutions, Medtronic, Mellon Medical, and Suturion. Competition centers on workflow fit, procedural specialization, ease of use, and compatibility with minimally invasive and robotic environments rather than on a single universal technology standard.

Johnson & Johnson MedTech is positioned around integration of Ethicon instrumentation with the OTTAVA robotic surgical system and its Polyphonic digital ecosystem. Its June 2025 launch of the ETHICON 4000 Stapler, intended for open and laparoscopic surgery and planned for future exclusive use with OTTAVA, demonstrates the strategic value of linking surgical instruments to a broader platform roadmap. The implication for automated suturing is that platform compatibility can become a procurement advantage where hospitals seek fewer interfaces across the operating room.

Boston Scientific's recent acquisitions reflect a continued emphasis on minimally invasive therapeutic adjacencies. The company completed its approximately USD 3.7 billion acquisition of Axonics in November 2024 after announcing the acquisition of Silk Road Medical, valued at approximately USD 1.16 billion, in June 2024. These transactions do not establish an automated-suturing claim on their own; they indicate that portfolio breadth in minimally invasive care can strengthen access to physician networks and procedural settings relevant to specialized surgical technologies.

Medtronic's Hugo robotic-assisted surgery system received CE Mark approval for LigaSure technology in July 2025 for gynecological, general, and urological procedures in Europe. ^{[8]Medtronic, Medtronic Secures CE Mark for LigaSure Technology on Hugo Robotic-Assisted Surgery System. news.medtronic.com} The development underscores how energy, closure, and robotic technologies increasingly compete through system-level compatibility. Smaller and specialized companies, including Anchora Medical, ErgoSuture, LSI Solutions, Mellon Medical, and Suturion, can differentiate where focused clinical design, procedure-specific utility, or alternative commercial models address needs not fully served by broad platform portfolios.

Recent Industry Developments

• On November 6, 2025, Nitinotes Ltd. received CE Mark approval for EndoZip, described as the first fully automated suturing platform for endoscopic sleeve gastroplasty. The approval enables commercialization across the European Union and other CE Mark-accepting markets; the company also identified a pivotal U.S. IDE trial as its next regulatory step.

• On July 7, 2025, Corza Medical launched an expanded Onatec Ophthalmic Suture Portfolio comprising nearly 130 products for ophthalmic and oculoplastic surgery. Corza identified the portfolio as the only fully dedicated ophthalmic suture portfolio from a single provider.